Investor attention has returned to Sarepta Therapeutics amid reports of the biotech firm's vigorous legal strategy to protect ...

Solid Biosciences Inc. (NASDAQ:SLDB) is one of the stocks that will double in 2026. On December 4, Needham analyst Gil Blum ...

There is no cure for the rare disease Hereditary Spastic Paraplegia (HSP), but researchers from Drexel University's College ...

There is no cure for the rare disease Hereditary Spastic Paraplegia (HSP), but researchers from Drexel University’s College ...

Determining which patients should receive the treatment will still require individual risk-benefit assessments, experts say.

Research by University of Sydney scientists has uncovered a mechanism that may explain why glioblastoma returns after ...

With notable therapies from Biogen, Sarepta and MacroGenics failing to show efficacy in pivotal or confirmatory trials, experts question the use of biomarker evidence for approval while one former ...

A mom was overjoyed when she learned a gene therapy treatment could save her child's life, until she found out no one would cover the $2 million price tag.

A new class of life-saving drugs is helping children who once had no hope. But some carry a price tag of millions for a ...

Once the exchange agreements close, Sarepta will have $893.4 million in debt due in 2030 following previous refinancing it announced in August.